Anthem Biosciences shares traded 2.01% higher at ₹825.45 on Monday after the company reported a strong fiscal year 2026. The firm achieved a net profit of ₹591.79 crore, up from ₹451.26 crore in the previous year, supported by improved profit margins and a very low debt-to-equity ratio.
Anthem Biosciences stock saw a 2.01% increase to trade at ₹825.45 on Monday, following the release of financial results for the fiscal year ending March 2026. The company reported consolidated revenue of ₹2,124.33 crore, marking an improvement over the ₹1,844.55 crore recorded in March 2025. Net profit for the same period rose to ₹591.79 crore, compared to ₹451.26 crore in the previous year.
The company’s latest financial report highlights an operational focus on efficiency. The operating margin reached 40.27%, while the net profit margin stood at 27.85% for the fiscal year ending March 2026. A key feature of the company’s balance sheet remains its minimal reliance on debt, with a reported debt-to-equity ratio of 0.02. This low debt level often provides companies with more flexibility during periods of capital expansion or market uncertainty.
Financial Health and Growth Indicators
The company's growth in profitability was reflected in its earnings per share, which rose to ₹10.55 from ₹8.07 in the previous year. Additionally, the return on equity improved slightly to 19.45%, up from 18.72% in March 2025. The company also demonstrated strong cash generation, with cash flow from operating activities increasing to ₹844 crore in March 2026 from ₹418 crore in the prior year. This trend suggests the company is effectively converting its reported profits into cash.
Performance for the Quarter Ending June 2026
For the first quarter of the current fiscal year, ending June 2026, Anthem Biosciences reported consolidated revenue of ₹418.22 crore and a net profit of ₹119.94 crore. Corporate updates from the firm include the conclusion of its 20th Annual General Meeting and the distribution of a final dividend of ₹2.00 per share, which had an effective date of June 25, 2026. The company also recently filed its earnings call transcript on July 22, 2026.
Investors may continue to track how the company maintains its high operating margins and low debt levels in upcoming quarters. A key monitorable for the business will be its ability to sustain these profit margins amid changing input costs or competitive pressures in the sector. Future updates regarding the company’s growth strategy and capital spending plans will likely be found in subsequent regulatory filings and quarterly reports.